Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT07638566 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT07638566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07638566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Lead sponsor
argenx
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
August 31, 2031
Enrollment
6 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy (cidp), cidp, cidp (chronic inflammatory demyelinating polyradiculoneuropathy)